biologics

Brought to you by:
RSV respiratory syncytial virus
Biotech

Vicebio hauls in $100M series B to push RSV shot through phase 1

The respiratory syncytial virus space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.
James Waldron Sep 23, 2024 3:00am
Cutting a rope knot

Potential new Alzheimer's drugs target tangles of tau

Sep 19, 2024 2:42pm
games game controller controller computer

New cell therapy biotech emerges from the lab of George Church

Sep 19, 2024 6:30am
Opera theatre

Novo Nordisk signs $530M biobucks deal to sing in Korro's opera

Sep 16, 2024 9:40am
Male and female superheroes posing in fluttering cloaks

ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial

Sep 14, 2024 2:30am
playing cards

Oncternal stock sinks 60% amid layoffs, trial terminations

Sep 12, 2024 10:51am